C4 Therapeutics to Participate in Upcoming Conferences
Rhea-AI Summary
C4 Therapeutics (Nasdaq: CCCC) announced management participation in several upcoming healthcare and oncology conferences. Events include TD Cowen’s 7th Annual Oncology Innovation Summit on May 26, 2026, the Jefferies Global Healthcare Conference on June 3, 2026, and the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026.
Fireside chats and 1x1 meetings will be held virtually and in person, with live webcasts and 90‑day archived replays accessible via the company’s investor relations website.
Positive
- None.
Negative
- None.
News Market Reaction – CCCC
In the May 20 session, CCCC gained 5.47%, reflecting a notable positive market reaction. Argus tracked a peak move of +9.2% during that session. Our momentum scanner triggered 20 alerts that day, indicating elevated trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 12 | Q1 2026 earnings | Neutral | +0.0% | Reported lower revenue and net loss with solid cash runway and pipeline progress. |
| Apr 09 | Roche collaboration | Positive | -2.4% | Expanded Roche partnership with $20M upfront and over $1B potential milestones. |
| Mar 25 | Phase 1b trial start | Positive | +7.6% | First patient dosed in Phase 1b cemsidomide plus elranatamab multiple myeloma study. |
| Mar 09 | Inducement option grant | Neutral | -13.1% | Announced non-qualified stock option grant to a new employee under Nasdaq rules. |
| Feb 26 | FY 2025 earnings | Positive | +0.4% | Reported 2025 results, cash runway to end of 2028, and cemsidomide Phase 2 progress. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Most past news events saw price moves aligning with the news tone, with one partnership announcement showing a negative divergence despite seemingly positive terms.
Over recent months, C4 Therapeutics reported earnings on Feb 26, 2026 and May 12, 2026, highlighting cash runway into 2028 and advancing cemsidomide into Phase 2 and Phase 1b studies. It expanded a key Roche collaboration on Apr 9, 2026, initiated a Phase 1b multiple myeloma trial on Mar 25, 2026, and disclosed an inducement stock option grant on Mar 9, 2026. Today’s conference-participation announcement fits within an ongoing pattern of visibility-building alongside pipeline and partnership progress.
Key Terms
targeted protein degradation medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
WATERTOWN, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today announced that C4T management will participate in the upcoming conferences.
TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA
- Management will participate in a virtual fireside chat on May 26, 2026, at 2:30 pm ET.
2026 Jefferies Global Healthcare Conference
- Management will participate in a fireside chat on June 3, 2026, at 8:45 am ET, taking place in New York, New York.
Goldman Sachs 47th Annual Global Healthcare Conference
- Management will participate in 1x1 meetings on June 10, 2026, taking place in Miami, FL.
The live webcasts will be available on the Investors section of the company’s website at www.c4therapeutics.com. Archived replays of the webcasts will be available for approximately 90 days following the events.
About C4 Therapeutics
C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO® platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit www.c4therapeutics.com.
Contacts:
Investors:
Courtney Solberg
Associate Director, Investor Relations
CSolberg@c4therapeutics.com
Leah Gibson
Vice President, Investor Relations & Communications
LGibson@c4therapeutics.com
Media:
Loraine Spreen
Senior Director, Corporate Communications & Patient Advocacy
LSpreen@c4therapeutics.com
